BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05275400 (Insulin Efsitora Alfa Insulin… in Type 2 Diabetes): BVCT ex-ante prediction vs. reported outcome

On 26 Nov 2022, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 5 Sep 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (non-inferior).

Clinical Trial

NCTID
NCT05275400
Acronym
QWINT-3
Drug Name
Insulin Efsitora Alfa (LY3209590) Insulin Degludec
Drug MoA
once-weekly insulin treatment
Drug Modality
protein biologic
Drug Class
Best-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Type 2 Diabetes
Human Patients
986
Sponsor
Eli Lilly and Company
Phase
Phase 3

Prediction of , index 720

Prospective Prediction
Prediction Index
720
Prediction Date
Commercial Prediction
SUCCESS (non-inferior)
Technical Prediction
SUCCESS (non-inferior)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
649 days in advance
Readout Data Interpretation
-0.86% (efsitora) vs -0.76% (degludec) HbA1C at week 26.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (non-inferior)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Phase
Phase 3
Status
Completed
Enrollment
986
Lead sponsor
Eli Lilly and Company
Conditions
Type 2 Diabetes
Interventions
DRUG: Insulin Efsitora Alfa; DRUG: Insulin Degludec
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2022-03-08
Primary completion
2024-05-15
Completion
2024-05-15
Results first posted
2025-06-03
Primary outcomes
  • Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26)

NCT05275400 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials